前收市價 | 23.87 |
開市 | 24.00 |
買盤 | 0.00 x 0 |
賣出價 | 0.00 x 0 |
今日波幅 | 24.00 - 24.96 |
52 週波幅 | 7.38 - 39.60 |
成交量 | |
平均成交量 | 76,237 |
市值 | 60.189M |
Beta 值 (5 年,每月) | 0.58 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -9.71 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ:NVDA). The sector is also getting a lift from the U.S. Federal Reserve’s decision to stop raising rates and its suggestions that it will cut rates later this year. Lower rates make it much easier for drug makers to obtain funds to finance the development of pharmaceuticals. Meanwhile, many pharmaceutical firms have rather low valuations because they dropped
Some investors believe that the market is always correct and that stock prices always accurately reflect reality. As a result, they will rarely if ever buy stocks that are tumbling and that are out of favor with the market. But, that philosophy is provably misguided because there have been many cases in which tumbling stocks have come roaring back. One such example that comes to mind is Tesla (NASDAQ:TSLA). In late 2022 and early 2023 the market was convinced that Tesla’s revenue and profits wou